Form 4: Abbott Laboratories Director Michael F. Roman Reports Acquisition of Stock Equivalent Units

Director Michael F. Roman reports acquisition of Abbott Laboratories stock equivalent units through director fees.

Summary

• On March 31, 2024, Michael F. Roman, a director of Abbott Laboratories, acquired 310 stock equivalent units.
• These units were obtained as director fees and are payable in cash, typically at age 65 or upon retirement from the board.
• The stock equivalent units mirror the return of Abbott shares.
• The price of the stock equivalent units was $113.66.
• Following the transaction, Roman directly owns 3,650 stock equivalent units, which includes units acquired through dividend reinvestment.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, indicating stability and alignment of interests. It's a neutral to slightly positive signal.

Positives

• The acquisition of stock equivalent units demonstrates the director's continued investment in Abbott Laboratories.
• The dividend reinvestment feature allows for growth in holdings over time.

Future Outlook

The stock equivalent units will be paid out in cash generally at age 65 or upon retirement from the board.

Industry Context

Directors often receive compensation in the form of stock or stock equivalent units to align their interests with those of shareholders. This Form 4 filing reflects a standard practice of compensating board members.

Comparison to Industry Standards

• Director compensation packages vary across the pharmaceutical industry, but equity-based compensation is a common practice.
• Companies like Johnson & Johnson and Pfizer also utilize stock options and restricted stock units as part of their director compensation plans.
• The specific value and structure of these packages depend on factors such as company size, performance, and industry benchmarks.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by aligning the director's interests with the company's performance.

Key Dates